Phaseline

Companies › Staidson (Beijing) Biopharmaceuticals

Staidson (Beijing) Biopharmaceuticals: clinical trials, targets and expected readouts

3 active drug programs in 4 registered trials: 2 Phase 3, 1 Phase 2, 1 Phase 1; Respiratory, Immunology, Genitourinary, Ophthalmology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BDB-001 injection–Phase 3ANCA Associated Vasculitis (AAV)Apr 2027
STSA-1002 injection–Phase 3Acute Respiratory Distress Syndrome (ARDS)–
STSP-0902 ophthalmic solution
Unclear - mechanism not stated in registry
–Phase 2Neurotrophic Keratitis; Oligozoospermia–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06975748STSP-0902 ophthalmic solutionPhase 2Neurotrophic KeratitisOphthalmologyApr 2026
NCT07208591STSA-1002 injectionPhase 3Acute Respiratory Distress Syndrome (ARDS)RespiratoryJul 2026
NCT06948799STSP-0902 ophthalmic solutionPhase 1OligozoospermiaGenitourinaryJul 2026
NCT07168161BDB-001 injectionPhase 3ANCA Associated Vasculitis (AAV)ImmunologyApr 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Priovant Therapeutics Sitala Bio Prana Therapies Enveda Therapeutics Lubris Bio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.